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Microbeam radiation therapy (MRT), a preclinical form of radiosurgery, uses
spatially fractionated micrometre-wide synchrotron-generated X-ray beams. As
MRT alone is predominantly palliative for animal tumors, the effects of the
combination of MRT and a newly synthesized chemotherapeutic agent JAI-51
on 9L gliosarcomas have been evaluated. Fourteen days (D14) after
implantation (D0), intracerebral 9LGS-bearing rats received either MRT,
JAI-51 or both treatments. JAI-51, alone or immediately after MRT, was
administered three times per week. Animals were kept up to 20 weeks after
irradiation or sacriﬁced at D16 or D28 after treatment for cell cycle analysis.
MRT plus JAI-51 increased signiﬁcantly the lifespan compared with MRTalone
(p = 0.0367). JAI-51 treatment alone had no effect on rat survival. MRTalone or
associated with JAI-51 induced a cell cycle blockade in G2/M (p < 0.01) while
the combined treatment also reduced the proportion of G0/G1 cells. At D28
after irradiation, MRTand MRT/JAI-51 had a smaller cell blockade effect in the
G2/M phase owing to a signiﬁcant increase in tumor cell death rate (<2c) and a
proportional increase of endoreplicative cells (>8c). The combination of MRT
and JAI-51 increases the survival of 9LGS-bearing rats by inducing
endoreduplication of DNA and tumor cell death; further, it slowed the onset
of tumor growth resumption two weeks after treatment.
Keywords: microbeam radiation therapy; JAI-51 chemotherapy; brain tumors.
1. Introduction
Microbeam radiation therapy (MRT) is an alternative form of
brain tumor radiosurgery which is being developed worldwide,
to a large extent at the European Synchrotron Radiation
Facility (France) (Slatkin et al., 1992). It uses synchrotron-
generated X-rays spatially fractionated into lattices of quasi-
parallel microbeams (tens of micrometres wide, hundreds of
micrometres spaced on-centre) (Slatkin et al., 1994, 1995).
Orthogonal crossﬁred irradiations performed on a 9L glio-
sarcoma (9LGS) model implanted in rat brains showed that
MRT increases signiﬁcantly the median survival times of
irradiated animals without severely impairing unidirectionally
irradiated ipsilateral or contralateral brain tissues (Serduc et
al., 2008; Smilowitz et al., 2006; Dilmanian et al., 2002; Laissue
et al., 1998). Tumor control might be related to a preferential
effect of MRT on tumor vessels: ﬁrst evidence has recently
been given in vivo (Bouchet et al., 2010); recent experimental
data showed a signiﬁcant decrease in tumor blood volume
after MRT, associated with an 80% tumor control rate
(Bouchet et al., 2010). However, despite the high radiation
doses used (Serduc, Bouchet et al., 2009; Serduc, Bra¨uer-
Krisch et al., 2009; Bouchet et al., 2010), radio-resistant 9LGS
(Kim et al., 1999) was not totally sterilized and some tumor
cells located at the tumor margins kept proliferating [Ki67
positive labelling (Bouchet et al., 2010; Serduc, Bouchet et al.,
2009)].
Clinical brain tumor treatment is often based on chemo-
therapy and radiotherapy (Stupp et al., 2005; Stupp & Roila,
2008). Chemotherapy, adjuvant to radiotherapy, contributes to
tumor control by decreasing mitotic activity of and inﬁltration
by surviving tumor cells (Bauman et al., 1999), but the median
overall lifespan of glioblastoma-bearing patients has only
increased by 2.5 months in the course of the last 30 years.
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Recent clinical trials have used bevacizumab and irinotecan
on recurrent malignant glioma; toxicity was acceptable, but
the treatment resulted in only 38% probability for six months
progression-free survival (Vredenburgh, Desjardins,
Herndon, Dowell et al., 2007; Vredenburgh, Desjardins,
Herndon, Marcello et al., 2007). Currently, there is no other
regimen for glioblastoma treatment than the Stupp protocol
(Stupp et al., 2005), which ends up with a low beneﬁt in terms
of overall survival. Some studies have described the anti-
mitotic potential of ﬂavonoid derivatives and their capacity to
reverse multidrug resistance (Jeong et al., 2007; Nakagawa-
Goto et al., 2010; Duraj et al., 2005). Therefore, we have used a
new chalcone (JAI-51) for the present study, a microtubule
polymerization inhibitor that we have recently developed;
JAI-51 has shown promising results on glioma models in vitro
(Boumendjel et al., 2008) and in vivo (rodents) (Boumendjel et
al., 2009). Chalcones that are ﬂavone precursors have been
investigated for their antiproliferative effect; ﬂavonoids are
polyphenols present in fruits, vegetables and many other
comestibles. Colchicines, vinca alkaloids and taxanes are
among many other natural substances that affect microtubular
dynamics (Boumendjel et al., 2008).
In this work we have evaluated for the ﬁrst time the asso-
ciation of MRT with JAI-51 for the treatment of 9LGS
implanted in rat brains, particularly the effects on the median
survival time of those rats. Further, we have characterized the
effect of both treatments, alone or combined, on the tumor cell
cycle ex vivo.
2. Materials and methods
All operative procedures related to animal care strictly
conformed to the guidelines of the French Government
(licenses 380324/380456 and A3818510002); they were
reviewed by the Internal Evaluation Committee for Animal
Welfare of the ESRF. The anesthetic procedure used in this
study was isoﬂurane (5% in air) for induction and an i.p.
injection of xylazine/ketamine (64.5/5.4 mg kg1) for main-
tenance.
2.1. Tumor implantation
Ninety-four anesthetized male Fisher 344 rats were
implanted with 104 9LGS cells in the right caudate nucleus as
described elsewhere (Serduc, Bra¨uer-Krisch et al., 2009).
Animals bearing 9L gliosarcoma were randomly divided into
four groups: untreated controls [‘Control’ (n = 26)], rats
subjected to chemotherapy alone [‘JAI-51’ (n = 15)], rats given
MRT 14 days after tumor implantation [‘MRT’ (n = 26)], rats
with MRT plus chemotherapy [‘MRT/JAI-51’ (n = 27)].
Thirty-two rats were then culled at day 16 (D16) or D28 after
treatment for cytometry studies (n = 32) and the others kept
for survival analysis (n = 62).
2.2. Chemotherapy
The chalcone derivate JAI-51 was obtained by the
condensation of 20,40,60-trimethoxyacetophenone with 1-
methylindolyl-3-carboxaldehyde in the presence of KOH in a
mixture of water and methanol. Freshly prepared aqueous
JAI-51 solution (48 mL JAI-51 stock solution 2M + 192 mL
DMSO + 11.8 ml PBS) was administered to animals through
i.p. injections (5.0 ml kg1 body weight) three times weekly
with intervals of two days for four weeks. Chemotherapy
(combined or not with radiation treatment) started 14 days
after implantation, i.e. at the same day as MRT (D0).
2.3. Microbeam radiation therapy
Brain tumor irradiations were performed at the European
Synchrotron Radiation Facility (ID17) as described previously
(Serduc, Bouchet et al., 2009). The X-ray spectrum extended
from approximately 50 to 350 keV (median energy around
90 keV). The dose rate was 16000 Gy s1. The beam was
spatially fractionated into a 1 cm-wide array of microbeams by
using a multi-slit collimator (Bra¨uer-Krisch, Requardt et al.,
2009). Two orthogonal arrays were used, each composed of 50
14 mm-high 50 mm-wide microbeams spaced 200 mm on-
centre. The in-beam skin entrance dose was 480 Gy. Animal
immobility during exposure was checked on three control
video screens. The whole irradiation procedure lasted <2 min.
2.4. Dosimetry
The spatial conﬁguration of the microbeams (width and
spacing) was checked microscopically in radiochromic ﬁlms
(Gafchromic, HD-810) (Crosbie et al., 2008) to ensure the
correct alignment of the multi-slit collimator and thus the
homogeneity of the dose distribution. No experimental dosi-
metry studies were performed. Monte Carlo dose computa-
tions, using a rat-head phantom (Siegbahn et al., 2006) for this
irradiation geometry, were carried out for a unique microbeam
array (Fig. 1).
2.5. Survival analysis
The time between implantation and death was recorded as
the survival time; one day was added in cases of euthanasia.
Kaplan Meier survival data were plotted versus time after
tumor implantation. The survival curves were compared using
a log rank test in Prism (GraphPad Software, San Diego,
USA).
2.6. Cytometry
Blood cells were counted in a Beckman apparatus in control
(n = 6), JAI-51 (n = 5), MRT (n = 14) and MRT/JAI-51 (n = 7)
treated animals. At D16 and D28 after implantation the brains
were excised and cut at the tumor injection site by means of a
pre-cooled Kopf matrix (David Kopf Instruments, USA).
1 mm3 tumor specimens were taken and used to make imprints
on glass slides and air dried. DNA content was measured
in 200 tumor cells per sample under a microscope (Zeiss,
Germany) at the absorption maximum for the Feulgen stain,
546 nm, in areas chosen at random. Calibration was performed
with human lymphocytes and normal glial cells as internal
reference to deﬁne the normal diploid (2c) value. These
measurements assess the DNA distribution pattern of the
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tumor cell population. The ploidy of the 9L cell line which was
used for injection was controlled by ﬂow cytometry. The
average DNA content in the G0/G1 phase of the 9LGS cell
line was 3.5c. The same data were found cytometrically on
Feulgen-stained slides: the ﬁrst peak in DNA content, corre-
sponding to the G0/G1 phases, was between 3c and 4c, and for
G2/M between 6.5 and 7.5c. Cells with DNA content between
4c and 6.5c were assigned to the S phase. Cells with DNA
contents lower than those of G0/G1 cells displayed the
morphology of apoptotic/necrotic cells. Cells with DNA
contents >7.5c were considered as cells that underwent
endoreduplication. For each group, the mean  one standard
deviation (SD) was calculated for the cell population in each
phase and presented in Fig. 3. Statistical analyses were
performed using the GraphPad Prism program; a two-way
ANOVA test was used (Bonferroni post-tests). Values were
considered signiﬁcantly different when p < 0.05.
3. Results
3.1. Dosimetry
The dose proﬁle for a single array of the microbeam is
plotted in Fig. 1. The peak dose, deposited at a depth of 1 cm
in rat brain, was 418 Gy, and generated a valley dose of
18.6 Gy (peak-to-valley dose ratio ’ 22.4).
3.2. Survival
Fig. 2 shows that rats in the control and the JAI-51 group
survived for a short time, 19 (1.5) and 18 (1.8) days after
tumor inoculation, respectively. MRT signiﬁcantly increased
the median survival time (MST) of irradiated rats (186%, p <
0.001). When both treatments were applied, a signiﬁcant
increase in lifespan was found between the MRT (MSTof 35.5
days) and MRT/JAI-51 groups [MST of 48 days after
implantation, 252% (p < 0.001) and 135% (p = 0.0367)
compared with the control and MRT groups, respectively].
3.3. Cytometry
Fig. 3 shows the repartition of the cells in the different
phases of the cell cycle at D16 and D28. At D16 there was no
difference in phase distribution between the control and JAI-
51 groups. MRT induced a signiﬁcant arrest in the G2/M phase
(p < 0.001) and a decrease in the G0/G1 population (p < 0.01).
In the MRT/JAI-51 group, G2/M and G0/G1 populations were
signiﬁcantly higher and lower, respectively, than those found
in the control group (p < 0.001). A signiﬁcant difference was
found in the G0/G1 population between MRT/JAI-51 and
MRT groups (20.5%, p < 0.05).
At D28, MRT irradiated tumors exhibited the same cell
cycle proﬁle as the unirradiated control group (p > 0.05 for
each population). The G0/G1 cell population was found to be
higher in the MRT group than in the MRT/JAI-51 group (p <
0.05). This may be due to the increases in the <2.5c and >8c
population in the MRT/JAI-51 at D28. The hyperploidy values
obtained for the different groups were compared with those of
the control group. Only the hyperploidy in the MRT/JAI-51 at
D28 was signiﬁcantly higher than the control value (p =
0.0007).
3.4. Blood cell counts
The total blood cell counts carried out at D16 and D28 are
shown in Table 1. None of the blood count values in the MRT/
JAI-51 group showed signiﬁcant differences from the control
research papers
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Figure 2
Survival curves of rats bearing intracerebral 9LGS (grey), treated by JAI-
51 (dashed black), irradiated by MRT (dashed grey) or treated by MRT
and JAI-51 (solid black). MRT and/or JAI-51 were performed at day 14
after tumor implantation.
Figure 3
Histograms showing the cycle distribution in control 9LGS, MRT and/or
JAI-51 treated tumors at D16 and D28, i.e. two days and 14 days after
treatment start. Each treatment started at day 14 after implantation. The
different cell cycle phases, G0/G1, S, G2/M, endoreduplicative and
apoptotic/necrotic cells are represented in light grey, dark grey, black,
white and hashed histograms, respectively. *, **, ***: p < 0.05, 0.01, 0.001,
signiﬁcantly different from control (similar cell cycle stage). # p < 0.05.
Figure 1
Calculated dose proﬁle for a single microbeam array of a 10 mm 14 mm
irradiation ﬁeld. The peak-to-valley dose ratio calculated at a depth of
1 cm in a rat head is 22.4, resulting in a maximum valley dose of 18.6 Gy.
The in-microbeam entrance dose was 480 Gy, delivering a 418 Gy peak
dose at 1 cm depth.
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group. JAI-51 induced a signiﬁcant decrease in thrombocyte
number at D16 after treatment. The white blood cells count
in the MRT group at D28 was signiﬁcantly higher than that
measured in the control group (p = 0.02).
4. Discussion
We have investigated the relevance of the association between
a chalcone called JAI-51, inhibitor of tubulin polymerization,
and MRT, on intracerebral 9LGS in rats. Our results showed
that JAI-51 alone does not act on this tumor, but that it may be
effective if a radiation treatment is given prior to its admin-
istration. Indeed, the MST of MRT-treated animals increased
signiﬁcantly when MRTwas associated with JAI-51 treatment
(p = 0.0367). The increase in lifespan was associated with a
signiﬁcant increase in the proportion of cells blocked in G2/M,
as well as in proportions of endoreplicative (>8c peak) and
pyknotic/apoptotic cells (sub-G0/G1 peak) two days after the
start of the treatments.
All MRT studies performed on implanted brain tumors in
rodents showed signiﬁcant increases in lifespan of irradiated
animals [e.g. 186% versus unirradiated controls, p < 0.001
(Laissue et al., 1998; Serduc, Bouchet et al., 2009; Serduc,
Bra¨uer-Krisch et al., 2009; Serduc et al., 2008; Bouchet et al.,
2010)], in association with limited histological damage of
irradiated normal brain tissues (for a review, see Bra¨uer-
Krisch, Serduc et al., 2009). However, some previous works
revealed that a small percentage of brain tumor cells, 2%
according to Dilmanian et al. (2002), kept their proliferative
activity after ‘effective’ MRT. More recent experiments
conﬁrmed this hypothesis: Ki67 positive tumor cells were
found at the 9LGS margins after MRT (Bouchet et al., 2010;
Serduc, Bouchet et al., 2009; Serduc, Bra¨uer-Krisch et al., 2009;
Serduc et al., 2008). Here we show for the ﬁrst time that the
tubulin polymerization inhibitor JAI-51 used as adjuvant helps
in tumor control after MRT. Conversely, JAI-51 alone had a
signiﬁcant effect on subcutaneously implanted GL26 tumor
cells in mice by slowing tumor growth (Boumendjel et al.,
2009), but the tumor micro-environments were drastically
different between the two models studied. In the GL26
glioma, tumoral blood vessels were fenestrated, while the
9LGS exhibited a weakly disrupted blood–tumor barrier
(Bouchet et al., 2010; Lemasson et al., 2010). This factor might
have considerably limited the diffusion of the chemo-agent
(349 Da) from the blood into the tumor parenchyma; diffusion
of JAI-51 into 9LGS probably remained insufﬁcient to have a
signiﬁcant effect on tumor growth and survival. Thus, a major
obstacle to the efﬁciency of chemotherapy for brain tumors
may reside in the presence of the blood–brain (and blood–
tumor) barrier(s) which limit considerably the diffusion of
these molecules into the tumor (van Vulpen et al., 2002). We
recently demonstrated that similar MRT protocols (400 Gy,
50/200 mm), applied to 9LGS, speciﬁcally increased tumor
vessel permeability (Bouchet et al., 2010). Our present results
conﬁrm that a pre-irradiation of intracerebral 9LGS is
required to allow an uptake of JAI-51 that is capable of
exerting a signiﬁcant adjuvant effect.
The increase in MSTof rats which received both treatments
is therefore likely to be due to the synergistic effect of MRT
with JAI-51. It has been shown in vivo that MRT protocols
similar to that used in our study induced an increase in tumor
blood vessel permeability while no changes were observed in
normal brain tissue (Bouchet et al., 2010; Dilmanian et al.,
2003; Serduc et al., 2008). The radiation-induced increase in
the blood–tumor barrier might thus have allowed a prefer-
ential uptake of JAI-51 by the tumor. This hypothesis would
be in keeping with the signiﬁcant difference between the MRT
and MRT/JAI-51 groups, in proportions of G0/G1 cells
observed on D16. Indeed, MRT induced a signiﬁcant redis-
tribution of the cell cycle stages of tumor cells: a decreased
proportion of tumor cells in the G0/G1 stages (20%, p <
0.05, compared with the MRT group), as well as a blockade of
cells in G2/M as detected by a slight but non-signiﬁcant
increase of the proportion of G2/M and <2c cells. The longer
blockade in G2/M and the accumulation of <2c and >8c tumor
cells slowed tumor growth and explained, at least in part, the
prolonged survival obtained in the MRT/JAI-51 group. The
biological mechanisms of cell death induced by JAI-51,
described elsewhere (Boumendjel et al., 2008, 2009), correlate
with the results of our cell cycle study. At D28, the results of
cell cycle analysis in the MRT group were similar to those
noted in the control group, an indication that the tumor cells
that have survived after the irradiation were able to prolif-
erate after a short blockade in G2/M. Cancer cells may use
endoreduplication as means of survival during mitotic inhibi-
tion; for instance, some mutant cancer cells undergo endor-
eduplication rather than apoptosis upon treatment with anti-
mitotic drugs such as colcemid and vinblastine (Lee et al.,
2009). However, some of these polyploid cancer cells can
revert to the mitotic cell cycle by means of a process of
genome reduction, ‘depolyploidization’. Survival from anti-
mitotic drug effects by endoreduplication and depolyploidi-
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Table 1
Number of red blood cells (RBC), white blood cells (WBC) and thrombocytes (SD) counted in blood samples from rats having received either MRT,
JAI-51 or both treatments.
Cell counts were performed 2 and 14 days after treatment starts (D16 and D28). The symbol (*) indicates signiﬁcant difference from the control (p = 0.02).
T l1 = trillion per litre.
Day 16 Day 28
Blood content Control JAI-52 MRT MRT/JAI-52 MRT/JAI-52 MRT
WBC (g l1) 3.3 (1.7) 5.9 (2.9) 2.2 (2.2) 2.3 (1.2) 7.0 (1) 9.0 (1)*
RBC (T l1) 7.7 (1.5) 8.0 (0.5) 7.5 (0.7) 7.6 (1.1 8.0 (1) 8.0 (0.2)
Thrombocytes (g l1) 611 (202) 212 (174)* 568 (14) 488 (302) 716 (291) 868 (164)*
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zation may be the strategy of cancer cells aiming to become
less sensitive to anti-mitotic drugs (Lee et al., 2009).
In this study we applied the JAI-51 regimen that has been
used previously for the human glioblastoma cell line (GL26)
implanted in mouse legs (Boumendjel et al., 2009). The MSTof
the MRT/JAI-51 group might be increased by optimizing drug
delivery, especially by the delay between the ﬁrst injection and
MRT, a parameter that might be reﬁned by varying the timing
of the ﬁrst drug injection. Khil et al. (2000) showed that the
optimal choice of the time schedule for BCNU adjuvant
chemotherapy of the 9LGS tumor was directly linked to
signiﬁcant improvement of the animal survival. Furthermore,
the basic geometry chosen for tumor targeting in this study
could be improved by use of recent improvements developed
at the ESRF. Three-dimensional interlaced or interspersed
geometry (Serduc, Bra¨uer-Krisch et al., 2009; Serduc, Bra¨uer-
Krisch et al., 2010; Bra¨uer-Krisch et al., 2005) combined with
image-guided irradiation (Serduc, Berruyer et al., 2010) may
improve MRT efﬁciency, mainly by reducing the radiation-
induced normal brain tissue damage while delivering a high
(uniform) dose to the tumor.
To conclude, we report here for the ﬁrst time the potential
of a chalcone chemotherapy associated with MRT. The
adjunction of an antimitotic drug at an optimal time after
MRT might help in reducing the radiation dose to achieve an
even better sparing of normal tissues.
Enam Khalil contributed to this work during her sabbatical
leave which was ﬁnancially supported by the University of
Jordan, Amman, Jordan.
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